ABSTRACT
Some of the primary prevention strategies that are currently being implemented include use of genderspecific therapy for patients with Hodgkin’s disease. Adolescent females with Hodgkin’s disease are offered primarily chemotherapy-based regimens, and radiation therapy to the chest area among females is reserved for patients considered at high risk of local relapse. This strategy is aimed to reduce the risk of radiation-associated breast cancer among female survivors of Hodgkin’s disease. Another example of a primary prevention strategy would be identification of patients heterozygous for drug-metabolizing enzymes before initiation of therapy for the primary cancer. This could lead to modification of therapy resulting potentially in a decrease in the incidence of second cancers.
